Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Am J Cardiol ; 201: 123-130, 2023 08 15.
Article in English | MEDLINE | ID: mdl-37385163

ABSTRACT

There is a paucity of data on the prognostic impact of mitral annular calcification (MAC) in patients who underwent transcatheter aortic valve implantation (TAVI) with conflicting results being reported by the studies that are published. Therefore, we performed a meta-analysis to assess the short-term and long-term outcomes of MAC in patients after TAVI. Of 25,407 studies identified after the initial database search, 4 observational studies comprising 2,620 patients (2,030 patients in the nonsevere MAC arm and 590 patients in the severe MAC arm) were included in the final analysis. Compared with patients with nonsevere MAC, the severe MAC group was associated with significantly higher incidences of overall bleeding (0.75 [0.57 to 0.98], p = 0.03, I2 = 0%) at 30 days. However, no significant difference was observed between the 2 groups for the rest of the 30-day outcomes: all-cause mortality (0.79 [0.42 to 1.48], p = 0.46, I2 = 9%), myocardial infarction (1.62 [0.37 to 7.04], p = 0.52, I2 = 0%), cerebrovascular accident or stroke (1.22 [0.53 to 2.83], p = 0.64, I2 = 0%), acute kidney injury (1.48 [0.64 to 3.42], p = 0.35, I2 = 0%), and pacemaker implantation (0.70 [0.39 to 1.25], p = 0.23, I2 = 68%). Similarly, follow-up outcomes also showed no significant difference between the 2 groups: all-cause mortality (0.69 [0.46 to 1.03], p = 0.07, I2 = 44%), cardiovascular mortality (0.52 [0.24 to 1.13], p = 0.10, I2 = 70%) and stroke (0.83 [0.41 to 1.69], p = 0.61, I2 = 22%). The sensitivity analysis, however, demonstrated significant results for all-cause mortality (0.57 [0.39 to 0.84], p = 0.005, I2 = 7%) by removing the study by Okuno et al5 and cardiovascular mortality (0.41 [0.21 to 0.82], p = 0.01, I2 = 66%) by removing the study by Lak et al.7 In conclusion, our meta-analysis corroborates the notion that isolated MAC is not an independent predictor of long-term mortality after TAVI and determines severe MAC to be a predictor of mortality at follow-up because of the higher incidence of mitral valve dysfunction associated with it.


Subject(s)
Aortic Valve Stenosis , Calcinosis , Heart Defects, Congenital , Heart Valve Diseases , Heart Valve Prosthesis Implantation , Stroke , Transcatheter Aortic Valve Replacement , Humans , Transcatheter Aortic Valve Replacement/methods , Mitral Valve/diagnostic imaging , Mitral Valve/surgery , Prevalence , Heart Valve Diseases/complications , Calcinosis/complications , Calcinosis/epidemiology , Stroke/epidemiology , Heart Defects, Congenital/complications , Aortic Valve Stenosis/epidemiology , Aortic Valve Stenosis/surgery , Aortic Valve Stenosis/complications , Treatment Outcome , Aortic Valve/surgery , Heart Valve Prosthesis Implantation/adverse effects
3.
Curr Probl Cardiol ; 48(8): 101233, 2023 Aug.
Article in English | MEDLINE | ID: mdl-35490770

ABSTRACT

Cardiovascular diseases (CVDs) are the leading cause of mortality globally. Wald and Law proposed the idea of a "polypill"; a fixed dose combination therapy (FDC) in the form of a single pill to curb the CVD epidemic. Such a drug would include the combination of a broad spectrum of drugs including cholesterol lowering drugs, antihypertensive drugs, antiplatelet drugs, anticoagulation drugs, and antiarrhythmic drugs, which are frequently integrated to combat specific CVDs. This "polypill" holds the potential to pose several advantages like increased compliance, improved quality of life, risk factor control, psychological relief, and cost effectiveness along with minimal side effects. Several trials (like TIPS, UMPIRE, PolyIran, etc.) have tested different treatment strategies to test the hypothesis of Wald and Law. Unlike the past, physicians are now highly aware of this new strategy. The future of polypill in the management of CVD lies in a strategy where polypills are treated supplementary to the already existing preventive care, which includes lifestyle modifications and efforts to reduce tobacco use.


Subject(s)
Cardiovascular Agents , Cardiovascular Diseases , Humans , Cardiovascular Diseases/epidemiology , Aspirin/adverse effects , Quality of Life , Drug Combinations , Platelet Aggregation Inhibitors/adverse effects , Antihypertensive Agents/therapeutic use , Cardiovascular Agents/therapeutic use
6.
Lancet ; 391(10123): 834-835, 2018 03 03.
Article in English | MEDLINE | ID: mdl-29508739
11.
J Forensic Leg Med ; 51: 27-33, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28734199

ABSTRACT

Endosulfan, an organochlorine (OC) insecticide, is a widely used agricultural pesticide, despite its life threatening toxic effects. In this review, the pharmacokinetics of endosulfan, mechanism of endosulfan toxicity, clinical presentations and management, histopathological findings, and toxicological analysis are described, in addition to its environmental toxicity. The toxic effects of endosulfan can affect many organs and systems presenting in a wide array of signs and symptoms. Although termed a restricted OC-classed pesticide, it continues to be used, especially in the developing world, owing to its beneficial effects on agriculture. Several cases of endosulfan poisoning have been reported from different regions of the world. Whether accidental or intentional, endosulfan ingestion proves to be fatal unless immediate, aggressive treatment is initiated. Management is mainly supportive as no antidote exists for endosulfan poisoning as yet. The use of endosulfan needs to be strictly regulated and eventually banned worldwide altogether to lower the current morbidity and mortality resulting from this pesticide. Additionally, monitoring biological samples, using non-invasive techniques such as breast milk sampling, can provide an effective method of observing the elimination of this environmentally persistent organic pollutant from the general population.


Subject(s)
Endosulfan/poisoning , Insecticides/poisoning , Autopsy , Endosulfan/analysis , Endosulfan/pharmacology , Female , Gas Chromatography-Mass Spectrometry , Humans , Insecticides/analysis , Insecticides/pharmacology , Maternal-Fetal Exchange , Mutagenesis , Poisoning/diagnosis , Poisoning/therapy , Pregnancy , Prenatal Exposure Delayed Effects
SELECTION OF CITATIONS
SEARCH DETAIL
...